A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
Public ClinicalTrials.gov record NCT03162536. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects With Relapsed or Refractory Hematologic Malignancies
Study identification
- NCT ID
- NCT03162536
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Industry
- Enrollment
- 190 participants
Conditions and interventions
Conditions
Interventions
- Nemtabrutinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 25, 2017
- Primary completion
- Sep 17, 2026
- Completion
- Sep 17, 2026
- Last update posted
- Sep 7, 2025
2017 – 2026
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Hospital ( Site 0140) | Scottsdale | Arizona | 85259 | — |
| UCLA Hematology & Oncology ( Site 0017) | Los Angeles | California | 90095 | — |
| Colorado Blood Cancer Institute ( Site 0225) | Denver | Colorado | 80218 | — |
| University of Michigan ( Site 0018) | Ann Arbor | Michigan | 48109 | — |
| Mayo Clinic - Rochester ( Site 0138) | Rochester | Minnesota | 58905 | — |
| Duke Cancer Center ( Site 0067) | Durham | North Carolina | 27710 | — |
| The Ohio State University Wexner Medical Center ( Site 0056) | Columbus | Ohio | 43210 | — |
| Tennessee Oncology, PLLC ( Site 0020) | Nashville | Tennessee | 37203 | — |
| UT Southwestern Medical Center ( Site 0116) | Dallas | Texas | 75390-8562 | — |
| University of Utah, Huntsman Cancer Institute ( Site 0122) | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03162536, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 7, 2025 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03162536 live on ClinicalTrials.gov.